Acquisition of resistance against UPR-induced cell death during chronic ER stress conditions might be an early and widespread mechanism in PDAC development, and targeting AGR2 could be a promising strategy to reverse this acquired survival advantage and increase cancer cell vulnerability. The gene discussed is AGR2; the disease is cancer.